Palisade Bio (NASDAQ:PALI) Earns “Buy” Rating from Maxim Group

Maxim Group reissued their buy rating on shares of Palisade Bio (NASDAQ:PALI) in a research note released on Wednesday, Benzinga reports. The brokerage currently has a $22.50 price target on the stock.

Palisade Bio Stock Performance

Shares of NASDAQ PALI opened at $7.74 on Wednesday. The stock’s fifty day simple moving average is $5.74 and its 200 day simple moving average is $7.47. Palisade Bio has a 52-week low of $3.82 and a 52-week high of $36.60.

Palisade Bio (NASDAQ:PALI) last issued its quarterly earnings results on Tuesday, March 26th. The company reported ($3.75) earnings per share for the quarter. Analysts predict that Palisade Bio will post -12.29 EPS for the current year.

About Palisade Bio

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults.